Scientists find clues on why COVID vaccine causes chronic health problems in some
Yale researchers recently made some discoveries about why certain people experience this condition, which they have dubbed "post-vaccination syndrome" (PVS).
In early findings, the team recognized "potential immunological patterns" that are unique to people with PVS. The hope is that this discovery will help to enable future treatments and therapies for those who are affected.
Is Mmr Vaccine Safe For Kids? Dr. Nicole Saphier Addresses Concerns As Measles Cases Rise
"This work is still in its early stages, and we need to validate these findings," said co-senior study author Akiko Iwasaki, Sterling Professor of Immunobiology at Yale School of Medicine, in a press release.
"But this is giving us some hope that there may be something that we can use for diagnosis and treatment of PVS down the road."
Read On The Fox News App
People with this condition may suffer from excessive fatigue, exercise intolerance, brain fog, insomnia and dizziness, according to the Yale researchers.
These typically develop within a day or two of vaccination and can worsen over time.
New Bat Coronavirus Discovered In China Sparks Pandemic Concerns
"It's clear that some individuals are experiencing significant challenges after vaccination. Our responsibility as scientists and clinicians is to listen to their experiences, rigorously investigate the underlying causes, and seek ways to help," said co-senior author Harlan Krumholz, professor of cardiology at YSM, in the release.
"Post-vaccination syndrome is real, and has been found [to occur] from many vaccines, including COVID," Dr. Marc Siegel, clinical professor of medicine at NYU Langone Health and Fox News senior medical analyst, told Fox News Digital.
The researchers analyzed blood samples from 42 study participants who experienced symptoms of PVS and 22 who did not.
Those with symptoms were shown to have lower levels of two types of white blood cells. People with PVS who had never had COVID also had lower levels of antibodies against the SARS-CoV-2 spike protein, likely because they tended to have fewer vaccine doses, according to the release.
"Fewer vaccine doses and no viral infection means the body's immune system has had little opportunity to develop a defense to the virus," said the researchers.
Some of the people with PVS also had higher levels of the SARS-CoV-2 spike protein, which enables the virus to penetrate and infect host cells. This has also been linked to a higher risk of developing long COVID.
"We don't know if the level of spike protein is causing the chronic symptoms, because there were other participants with PVS who didn't have any measurable spike protein — but it could be one mechanism underlying this syndrome," said Iwasaki.
In addition to the elevated spike proteins, other factors could increase the risk of post-vaccination syndrome. Those include autoimmunity, tissue damage and reactivation of Epstein-Barr virus (EBV), the researchers wrote.
"Akiko Iwasaka is a world-renowned immunologist at Yale who has studied COVID (and COVID vaccines) extensively," Siegel pointed out.
Click Here To Sign Up For Our Health Newsletter
"In this new study, she reports that in a very small percentage of those who received COVID vaccines (and experienced prolonged side effects), there may be the presence of persistent spike protein," Siegel confirmed.
"They may also experience immune disruption, which takes the form of elevations in inflammatory immune cells (CD8 and TN alpha) and a decrease in cells that help resolve inflammation and infection (CD4 helper cells)."
The researchers agreed that more studies are essential to guide diagnosis and treatment.
"We're only just starting to make headway in understanding PVS," said Krumholz. "Every medical intervention carries some risk, and it's important to acknowledge that adverse events can occur with vaccines."
For more Health articles, visit www.foxnews.com/health
"Our focus must remain on understanding what these people are experiencing through rigorous science and addressing the needs of those affected with compassion and an open mind."
Siegel agreed, adding, "This needs to be further studied in terms of understanding how common prolonged COVID vaccine side effects are and how to predict them and treat them."Original article source: Scientists find clues on why COVID vaccine causes chronic health problems in some
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Louisville boy makes medical history as first patient in US with new cochlear implant
DuJuan Broadus couldn't believe how loud the birds outside his bedroom window sounded. The buzzing of the cicadas near his grandmother's home in Georgetown was almost overwhelming. Having unknowingly lived with profound hearing loss for years, the world sounded so much more colorful than the Louisville native ever imagined. In December, DuJuan, now 11, went from having 'the hearing of a World War II veteran,' as one doctor put it, to becoming the first patient in the United States to receive a MED-EL FLEX34 cochlear implant. This new technology is the longest implant on the market and is designed for people, like DuJuan, who have an unusually large cochlea, which is the part of the ear that converts sound vibrations into signals the brain interprets as sound. If doctors had used a shorter model, DuJuan's hearing would have improved, but he wouldn't necessarily have access to such a dynamic range of frequencies, said Dr. Nathan Cass, a UK HealthCare otology and neurotology specialist, who implanted the FLEX34 in DuJuan's ear in December 2024. Specifically, lower, deeper sounds are limited, Cass said. If the electrode can't reach to the end of the patient's cochlea, they'll likely hear voices at a higher pitch. 'They'll say at their (cochlear implant) activation that voices sound kind of like Mickey Mouse,' Cass said. 'But one of the things that this new technology is aiming to try to help is to try to get people to get things to sound more natural.' With the help of the FLEX34, DuJuan now hears the world, and all the background noise that comes with it, at a completely different level. For the past eight months or so, it's been a daily adventure for him to learn and put names to sounds and background noises that his brain had never registered before. 'A lot of times it was really difficult, but I got used to it,' DuJuan told the Courier Journal. 'Now I can tell that the bird is a bird. I can tell a cricket is a cricket. I can tell a motorcycle is a motorcycle.' 'I didn't even know I had hearing loss' The journey to hearing and understanding what the world sounded like started well before DuJuan ended up at UK HealthCare. When DuJuan was about three years old, his parents noticed a speech impediment. His mother has a clear memory of him pointing to a motorcycle as a child, but pronouncing the word for it similar to the name 'Michael.' One of the first lines of intervention with speech is a hearing test. Studies have shown that about one to five children in about every 1,000 has hearing loss, according to the Centers for Disease Control and Prevention. More: Confused about the COVID-19 booster? Here's what children, pregnant women in Kentucky need to know DuJuan passed that first hearing test, and from there, his parents enrolled him in speech therapy. Over time, his speech improved, and he graduated from speech therapy in the third grade. But something still didn't seem right. His grades were strong in reading and math, but his fourth-grade teacher had concerns about how he responded when she spoke to him. She wasn't sure if he didn't understand the question or if he couldn't hear what she was asking. So Jefferson County Public Schools tested him for hearing loss, and this time he failed — dynamically. He was just 10 years old at the time, and was already in severe and profound stages of hearing loss. No one had noticed up until this point, though, because DuJuan is an incredibly bright and resilient child. Without knowing it, DuJuan had taught himself to read lips. He'd become so good at it over the years, that when his mother, Letisha Broadus, spoke to him in the car, he knew to crane his neck up so that he could see her lips moving in the rearview mirror. He thought that this was something that everyone needed to do. 'I didn't even know I had hearing loss at first,' he said. 'Once I knew, I asked my mom 'what is even hearing loss?'' Heartbroken for her son but also determined, Letisha tried to find an ear, nose and throat specialist in Louisville to help. The waitlists locally were months long, so doctors referred her to UK HealthCare's Ear, Nose and Throat Clinic in Lexington, which was ranked No. 37 in the nation by US News and World Report in 2024 for that specialty. The 70-mile trip to the doctors was worth it, if they could schedule a surgery for an implant sooner. In the meantime, DuJuan used a hearing aid, which typically helps patients with low or moderate hearing loss. The day they turned it on in March 2024 was unforgettable for the whole family. 'There were a lot of tears, and a lot of emotions because he could hear things for the first time,' Letisha remembered. When the doctor stapled something to his file, DuJuan's ears caught the quick, snap-like click a stapler makes for the first time, ever. 'Wow,' he told his mom. 'That's what that sounds like.' He had so many things to relearn. 'I wasn't able to stop smiling that day' On the day the Broaduses traveled to Lexington in December 2024 for the cochlear implant surgery, DuJuan was a little nervous, of course, but also excited for what else the implant might help him hear. There are only three companies in the world that manufacture cochlear implants. DuJuan and his parents selected MED-EL, which had released the longest implant currently on the market in 2023. The Food and Drug Administration approved it the July before DuJuan's surgery. DuJuan's cochlea was 38 millimeters long, and he's in the 5-7% of the largest cochleas in the country. It's rare enough that in the eight months that have followed since his surgery, Cass has only implanted one other FLEX34 on a patient. More: Their son died by suicide. Now this Louisville couple is helping other young adults The difference in those extra millimeters, though, is crucial for patients like DuJuan. The cochlea has two fluid-filled chambers lined with tiny hairs. When a sound occurs, it vibrates the fluid in the cochlea. Those impulses are translated into electrical signals that the brain interprets as sound. The farther the implant can reach into the chamber, the more natural the sound becomes in the brain. 'The vast number of sensory cells we have there allows for some of the richness of the sounds that we can understand, and the dynamic range of the frequencies is very large,' Cass explained. When they turned the implant on in the weeks that followed the surgery, DuJuan couldn't wait to hear the world the same way everyone else does. "I wasn't able to stop smiling that day," he remembers. DuJuan is a big fan of music. The hearing aid kept him from having to listen to it on full blast, but now the voices in the songs are clearer. With a shorter implant, the rap music he enjoys might sound like Mickey Mouse is trying to take cues from 50 Cent or Kendrick Lamar. The FLEX34 helps him hear music as everyone else does. Now he has access to lower, bass notes. More: 300 people in line? How hard-to-find bourbons made Buffalo Trace Distillery a cult favorite And that's important, because DuJuan has big plans to join the choir when he starts the sixth grade at Western Middle School for the Arts this school year. He's always been a musically inclined child. When DuJuan was a baby, his mother would sing little songs to him, and he'd somehow managed to reply with the same, proper note. And while he'll have to wait until he's older before his voice lowers enough to hit any bass notes himself — in the meantime, he certainly hears them more on tune than he ever has before. More: What is a cochlear implant? Learn more about device Reach features columnist Maggie Menderski at mmenderski@ Want to learn more? To learn more about cochlear implants, hearing loss, the FLEX34 and other electrodes available for hearing loss patients, visit This article originally appeared on Louisville Courier Journal: Louisville boy first patient in US with med-el-flex34 cochlear implant Solve the daily Crossword
Medscape
2 hours ago
- Medscape
Younger Adult CRC Still Rising: Time for That Colonoscopy?
This transcript has been edited for clarity. Welcome to Impact Factor , your weekly dose of commentary on a new medical study. I'm Dr F. Perry Wilson from the Yale School of Medicine. I am 45 years old. And I have been 45 years old for 8 months now. And I'm a doctor. A doctor who prides himself on being up to date on medical guidelines, practices, and evidence. And you know what I have not done yet? Not even made an attempt to do yet? Scheduled my screening colonoscopy. Let me be clear, this is not out of some high-minded concern for overdiagnosis or the issue of false positives in screening exams. This is pure, unadulterated, laziness. Or perhaps, if I'm being generous, I simply have too many other things going on in my life to take the 20 minutes to get this thing scheduled. I probably should, because the rate of colorectal cancer among people ages 45-49 has been going up steadily since at least the mid-90s and dramatically over the last few years. We need to figure out what's going on. We're going to dig into the rising incidence of so-called 'early onset' colon cancer in a minute, but let me point out that, in recognition of the changing demographics of the disease, the United States Preventive Services Task Force (yes, that same USPSTF that may soon be fired en masse by RFK Jr) changed their recommended starting screening age from 50 to 45 years of age in 2021. With a stroke of a pen, 45 million Americans were suddenly eligible for colon cancer screening, typically through colonoscopy or a fecal immunochemical test: that's the one you do at home that lets you know if there is microscopic blood in your stool. And now, 4 years later, we can look back and see the effect that change in screening criteria had. In fact, appearing this week in JAMA, we have a trio of papers looking at the issue of early-onset colorectal cancer from a few different angles: How to get younger people like me to screen, how much younger people like me are screening, and how much new colon cancer we are detecting. Let's start with the screening numbers. In Trends in Colorectal Cancer Screening in US Adults Aged 45 to 49 Years, Jessica Star at the American Cancer Society and colleagues used a nationally-representative health survey to look at screening across various age groups and over time. The primary results are here. You can see that screening is pretty rare among 40–44-year-olds and hasn't changed much over time. That seems right; guidelines currently suggest to start screening at 45, not 40. Moving into my age group, you see a dramatic increase from about 20% screening in 2019 and 2021 to 35% screening in 2023. This is about a 60% relative increase in baseline screening rates. It's not perfect, of course. People like me who haven't gotten around to screening yet are still in the majority, but it shows how guideline changes can move the needle on this stuff. Of course, it's worth noting that the Affordable Care Act (Obamacare) mandates that insurers cover any screening test recommended by the USPSTF. Paying for screening also increases screening. One concern people had about the change in guidelines was that all this new screening in younger people would crowd out screening in older people. The data, fortunately, doesn't show this. Screening rates were high and stable in the over 50 crowd over the past 5 years. If you're a believer in screening, you probably want to know how to improve rates among younger people like me. In another article in this week's JAMA , researchers led by Artin Galoosian at UCLA report out results from a randomized trial that tried four different strategies to increase the screening rate in people aged 45-49. A bit more than 20,000 individuals were randomized. A quarter of them were invited, via an online patient portal, to use the fecal immunochemical test (FIT) for screening. Another quarter were invited to do a screening colonoscopy. A quarter were invited to do either; they could choose which they preferred. And, finally, a quarter were simply mailed a FIT. Of the people invited to do FIT testing, 18% got some kind of screening, mostly colonoscopy. Of those invited to colonoscopy, 15% were screened. Of those given the choice between the two, 18% picked one or the other. But in those who just had the test show up in the mail, 28% completed screening. This is pretty powerful data. It confirms a fundamental principle of behavioral economics: People will do something if you make it easy for them. Anecdotally, if I opened the mail tomorrow and a FIT test was in there, I'm pretty sure I would do it. Since that isn't standard of care (yet), I need to call my PCP (who I haven't seen in like 5 years) and go through the rigamarole. But I'll do it. I will. I think. Now, I opened this commentary by mentioning that all of this research is driven by the simple observation that colorectal cancer rates are increasing in young people. A third paper in JAMA this week, Colorectal Cancer Incidence in US Adults After Recommendations for Earlier Screening, from Elizabeth Schafer and colleagues at the American Cancer Society, tracks those rates for us from 2006 on using the SEER database. There are some really interesting findings here. Let me start with this picture, the rate of any colon cancer diagnosis in individuals aged 45-49. You see a steady uptick, about 1% per year from 2006 on, and then a dramatic increase (about 12%) in the past few years. That's a scary graph. But I'll de-scare it a bit for you. Here is the graph for local colorectal cancer over that time period. These are early cancers that have not yet spread. It looks very similar. In fact, according to the paper, nearly all of that accelerated increase in the past few years is driven by early, local cancers. That is a strong signal that it is the increased screening that is leading to increased diagnosis, as opposed to some new environmental or other exposure. And, since early cancers are more treatable, we can potentially argue that this increase is actually a good thing. Better to detect now than later. But the rise in [colorectal cancer] in young people is not all due to screening. Here is the graph showing the rate of colorectal cancer with distant metastases over time. You see a steady increase — no big inflection that we can attribute to more screening. Nor would you expect there to be, as screening is really optimized to catch early cancers, not metastatic ones. Bottom line: If you hear headlines about a startling rise in colorectal cancer in young people, realize that there is nuance here. Yes, there has been a dramatic rise in the last few years, mostly because we are catching early cancers through screening. But there has also been a slower rise over a much longer time period. Over decades. Which leaves the question of… why? Why is colon cancer affecting younger and younger people over time? What has changed in our lives during the past 30 years? There is no smoking gun, but there are an awful lot of possibilities. I think the obesity epidemic is a big one here, and it will be interesting to see if these curves flatten in the GLP-1 era. But there are other possibilities: microbiome changes, ultraprocessed foods, even microplastics. It will take a bit more detailed epidemiology to get to the bottom of the increased risk in younger people. But, given the data, well, I should probably call my PCP and get that damn colonoscopy scheduled.
Politico
2 hours ago
- Politico
Will feds weigh in on religious vax carveouts?
Driving the Day RELIGIOUS VAX EXEMPTIONS — It's back-to-school season, which means parents are shuttling their kids to pediatricians for annual checkups — and advocates for and against states' exemptions to vaccine mandates for school entry are gearing up for a fight, Lauren reports. Vaccine skeptics have sought to make their case to the Trump administration's Religious Liberty Commission — created by executive order in May — for executive action to bolster religious carve-outs. But they face pushback from public health experts who warn that more exemptions could threaten public health, setting up another front in the vaccine wars. Four states — California, Connecticut, Maine and New York — don't offer religious exemptions to school vaccine requirements, and Massachusetts lawmakers are considering banning them. West Virginia provides exemptions after GOP Gov. Patrick Morrisey signed an executive order earlier this year invoking the state's religious freedom law. Some religious liberty groups have called on the federal government — which has no say in state vaccine mandates — to use federal education funding as leverage to expand religious opt-outs from school immunization requirements, pointing to a Clinton-era religious protection statute. Precedential web: Some vaccine law experts question how far the executive branch could go to nudge those outlier states toward accepting religious exemptions. The Supreme Court curtailed the Religious Freedom Restoration Act's application to the states in 1997, and administrative conditions on federal funding can't run afoul of Congress' directions. But proponents say those lawyers ignore more recent opinions that work in exemption advocates' favor, pointing to a Covid-19-era decision lifting in-home gathering restrictions on religious grounds and, more recently, the court's ruling in favor of parents who want to opt their children out of LGBTQ+-themed lessons in public schools. Shifting winds: The number of kindergarteners entering school with at least one vaccine exemption continues to tick up, with the CDC reporting last week that 3.6 percent had one in the 2024-2025 school year, compared with 2.2 percent a decade ago. Days before the updated data was released, the American Academy of Pediatrics reaffirmed its opposition to religious exemptions, arguing they should be abolished to protect public health. 'In practice, nonmedical exceptions based on religious belief can substantially limit the public health value of vaccine requirements for school attendance,' the group said in a statement. 'There is no practicable way for schools or other involved community partners to distinguish fairly among religious or other nonmedical claims.' What's next: The Religious Liberty Commission will hold a hearing next month on public education issues, giving exemption proponents another opening to make their case. It's unclear where the White House stands on the concept — a spokesperson didn't comment — but the first Trump administration's HHS pursued avenues to grant health care workers expanded 'conscience' protections and to allow imports of certain vaccines due to some patients' religious beliefs. IT'S TUESDAY. WELCOME BACK TO PRESCRIPTION PULSE. Your host is wondering whether concerns about a common allergy medicine's risks might catch the FDA's attention. Send tips to David Lim (dlim@ @davidalim or davidalim.49 on Signal) and Lauren Gardner (lgardner@ @Gardner_LM or gardnerlm.01 on Signal). Eye on the FDA NEW TOP LAWYER — FDA Commissioner Marty Makary named a longtime government attorney on Monday to be the agency's chief counsel, months after his first pick was torpedoed by Sen. Josh Hawley (R-Mo.). Sean Keveney, who most recently served as HHS's acting general counsel, served as a career civil servant at DOJ's civil rights division before becoming deputy general counsel at HHS in 2019, according to the department and his LinkedIn profile. His predecessor in the position, Hilary Perkins, was also a career DOJ lawyer whose appointment drew Hawley's ire before Makary's confirmation because of her record defending the Biden administration's abortion pill policies. While Perkins also defended the Trump FDA's mifepristone positions, that wasn't enough to overcome his opposition, and she ultimately stepped down days into the job. MDUFA KICKOFF — The FDA's medical device user fee program is not set to expire until Sept. 30, 2027, but the process to renew it has already begun. Despite HHS Secretary Robert F. Kennedy Jr.'s vocal distaste for the user fee programs, the Trump administration has made it clear they are committed to the monthslong process that will likely result in their renewal for another five years. Industry and FDA leaders — including FDA Commissioner Marty Makary and Center for Devices and Radiological Health Director Michelle Tarver — met Monday to discuss the potential sixth iteration of the medical device user fee program. 'While user fees support timeliness and predictability by providing FDA with additional resources, user fees are not a guarantee of approval,' AdvaMed's senior executive vice president, Janet Trunzo, said according to prepared remarks. 'They never have been, and they never should be.' In Congress SENATE PASSES FDA FUNDING — Before leaving town for the August recess, the Senate passed a bill to fund the FDA for fiscal 2026 as part of a minibus package by an 87-9 vote. The legislation, which funds the agency at $7 billion, is made up of $3.6 billion in taxpayer funds and $3.4 billion in user fee revenues. But it is unclear whether lawmakers will have to turn to a continuing resolution before government funding runs out at the end of September. The House Appropriations Committee previously advanced an FDA bill that funded the agency at a lower level. Research Corner BOOST FOR WOMEN'S HEALTH — The Gates Foundation said Monday it would spend $2.5 billion through 2030 to speed global women's research into maternal, menstrual, gynecological and sexual health. Pharma Moves Erika Sward is now chief advocacy officer at UsAgainstAlzheimer's. She previously was assistant vice president of national advocacy at the American Lung Association. Document Drawer FDA Commissioner Marty Makary met with Rep. John Joyce (R-Pa.) for an introductory meeting on July 24. He also met with People for the Ethical Treatment of Animals to discuss nonanimal testing approaches on July 21, according to newly posted public calendar disclosures. He also met with the leadership team of the Government Accountability Office on July 16 to discuss 'items of mutual interest.' WHAT WE'RE READING Top FDA cancer medicine regulator Richard Pazdur played a critical role in the rejection of Replimune Group's skin cancer therapy, STAT's Adam Feuerstein reports. Longevity companies are eyeing Montana as a potential hub for 'biohacking' treatments thanks to state laws embracing patients' 'right-to-try' experimental drugs, The Wall Street Journal's Alex Janin writes.
